Opens in a new tab
Thursday, 19 November 2026
EVIDENCE. INTERPRETED.
Advertisement · Remove ads
728 × 90
New Drug Approval

Dupixent Breaks New Ground in Pediatric Chronic Urticaria Care

The FDA has expanded Dupixent’s approval to include children aged two to 11 years with chronic spontaneous urticaria who remain symptomatic despite antihistamine therapy, supported by phase 3…

Written byVennela ReddyReviewed byPharmacally Editorial Team23 April 2026 · 3 min read
Fact-Checked
Gemini_Generated_Image_gw8fk0gw8fk0gw8f

FDA approves Dupixent (dupilumab) for children aged 2–11 years with chronic spontaneous urticaria, expanding treatment options for pediatric patients with uncontrolled disease.

The US Food and Drug Administration has approved Dupixent® (dupilumab) for children aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite treatment with second‑generation H1‑antihistamines, expanding its prior indication in patients aged 12 years and older.

CSU is a chronic inflammatory condition characterized by recurrent hives, often with angioedema and severe itching, that can markedly impair quality of life; many pediatric patients continue to experience uncontrolled symptoms despite standard therapy.

The approval is supported by the LIBERTY‑CUPID phase 3 program, including placebo‑controlled studies (Study A and Study C, NCT04180488) in patients aged 12 years and older, as well as pharmacokinetic data from the CUPIDKids study (NCT05526521) in younger children.

In these trials, dupilumab significantly reduced itch severity and overall urticaria activity at 24 weeks compared with placebo and increased the likelihood of achieving well‑controlled disease or complete response in the older adolescent and adult populations.

Safety findings were consistent with the drug’s established profile, with injection‑site reactions being the most commonly reported adverse events and no new safety signals identified in children.

Dupilumab is a monoclonal antibody that inhibits interleukin‑4 and interleukin‑13 signaling, key drivers of type 2 inflammation underlying CSU and related conditions and is administered as a subcutaneous injection with dosing based on age and weight.

Alyssa Johnsen, MD, PhD, Global Therapeutic Area Head, Immunology Development at Sanofi, noted that the approval provides a targeted treatment option for young patients with CSU whose disease remains uncontrolled despite existing therapies.

George D. Yancopoulos, MD, PhD, Board Co‑Chair, President and Chief Scientific Officer at Regeneron, highlighted that this represents the first biologic approval in the US for children 2–11 years with CSU and further reinforces the therapy’s established safety and broader role across type 2 inflammatory diseases.

Dupilumab is approved in more than 60 countries for multiple indications across age groups, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, CSU, chronic obstructive pulmonary disease, bullous pemphigoid, and allergic fungal rhinosinusitis, with over 1.4 million patients treated globally. It continues to be studied in additional conditions linked to type 2 inflammation.

Reference

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Study Details | NCT04180488 | Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID) | ClinicalTrials.gov

Study Details | NCT05526521 | A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids) | ClinicalTrials.gov

Advertisement · Remove ads
728 × 90
Reviewed by the Pharmacally Editorial Team
Every story is checked against primary sources.
Our editorial process →